GlucoTrack (GCTK) Competitors $4.89 +0.02 (+0.41%) Closing price 04:00 PM EasternExtended Trading$4.75 -0.14 (-2.86%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GCTK vs. FEMY, ALUR, NXL, IINN, BTCY, DHAI, INBS, MHUA, TNON, and CODXShould you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include Femasys (FEMY), Allurion Technologies (ALUR), Nexalin Technology (NXL), Inspira Technologies OXY B.H.N. (IINN), Biotricity (BTCY), DIH Holding US (DHAI), Intelligent Bio Solutions (INBS), Meihua International Medical Technologies (MHUA), Tenon Medical (TNON), and Co-Diagnostics (CODX). These companies are all part of the "medical equipment" industry. GlucoTrack vs. Its Competitors Femasys Allurion Technologies Nexalin Technology Inspira Technologies OXY B.H.N. Biotricity DIH Holding US Intelligent Bio Solutions Meihua International Medical Technologies Tenon Medical Co-Diagnostics GlucoTrack (NASDAQ:GCTK) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Do institutionals & insiders hold more shares of GCTK or FEMY? 10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 12.9% of GlucoTrack shares are held by company insiders. Comparatively, 11.5% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to GCTK or FEMY? In the previous week, Femasys had 1 more articles in the media than GlucoTrack. MarketBeat recorded 2 mentions for Femasys and 1 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 1.00 beat Femasys' score of 0.33 indicating that GlucoTrack is being referred to more favorably in the media. Company Overall Sentiment GlucoTrack Positive Femasys Neutral Do analysts prefer GCTK or FEMY? Femasys has a consensus price target of $7.33, suggesting a potential upside of 1,850.87%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than GlucoTrack.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GCTK or FEMY more profitable? GlucoTrack has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. GlucoTrack's return on equity of 0.00% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets GlucoTrackN/A N/A -352.05% Femasys -1,113.72%-713.74%-152.60% Which has more risk & volatility, GCTK or FEMY? GlucoTrack has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.64, suggesting that its share price is 364% less volatile than the S&P 500. Which has higher earnings & valuation, GCTK or FEMY? Femasys has higher revenue and earnings than GlucoTrack. Femasys is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlucoTrackN/AN/A-$22.60M-$56.60-0.09Femasys$1.63M7.51-$18.82M-$0.86-0.44 SummaryFemasys beats GlucoTrack on 9 of the 15 factors compared between the two stocks. Get GlucoTrack News Delivered to You Automatically Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GCTK vs. The Competition Export to ExcelMetricGlucoTrackMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.38M$11.02B$5.77B$9.91BDividend YieldN/A1.84%6.71%4.52%P/E Ratio-0.0921.7575.5426.08Price / SalesN/A30.97482.3489.45Price / CashN/A24.5936.9659.01Price / Book0.003.5911.446.09Net Income-$22.60M$212.34M$3.28B$266.14M7 Day Performance15.88%-2.29%0.84%0.28%1 Month Performance-16.12%8.54%7.15%4.14%1 Year Performance-99.85%-8.18%59.66%23.93% GlucoTrack Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GCTKGlucoTrackN/A$4.89+0.4%N/A-99.8%$4.38MN/A-0.095Positive NewsShort Interest ↓Gap DownFEMYFemasys3.5395 of 5 stars$0.38-27.0%$7.33+1,850.4%-66.7%$16.78M$1.89M-0.4430Short Interest ↓High Trading VolumeALURAllurion Technologies3.3444 of 5 stars$2.18-2.7%$22.83+947.4%-86.3%$16.70M$32.11M-0.17501Positive NewsShort Interest ↓NXLNexalin Technology1.8714 of 5 stars$0.85+1.5%$5.00+490.5%-7.8%$14.53M$174.81K-1.113Negative NewsShort Interest ↑IINNInspira Technologies OXY B.H.N.3.1339 of 5 stars$1.18+3.5%$2.00+69.5%-0.9%$14.39MN/A0.0020Short Interest ↓Analyst RevisionBTCYBiotricityN/A$0.57-12.9%N/A+54.2%$14.18M$12.06M-0.5340Gap UpHigh Trading VolumeDHAIDIH Holding US1.1145 of 5 stars$0.27-4.0%N/A-89.9%$13.25M$64.47M-0.90N/ANews CoverageShort Interest ↓Gap DownINBSIntelligent Bio Solutions0.1011 of 5 stars$1.46-0.5%N/A+16.9%$13.20M$3.05M-0.7110MHUAMeihua International Medical Technologies1.7035 of 5 stars$0.43+4.9%N/A-62.5%$13.08M$96.91M0.00620Short Interest ↓TNONTenon Medical1.3265 of 5 stars$1.31-5.8%$5.50+319.8%+162.1%$12.34M$2.95M-0.058News CoverageShort Interest ↑CODXCo-Diagnostics4.1221 of 5 stars$0.31-1.4%$5.50+1,660.6%-75.3%$12.20M$3.91M-0.27100 Related Companies and Tools Related Companies FEMY Alternatives ALUR Alternatives NXL Alternatives IINN Alternatives BTCY Alternatives DHAI Alternatives INBS Alternatives MHUA Alternatives TNON Alternatives CODX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GCTK) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GCTK Stock Alerts